Capricor DMD Drug Shows 76% Slowdown in Arm Decline Over 24 Months
Capricor Therapeutics reported strong open-label extension data for deramiocel in Duchenne muscular dystrophy at a global muscle disease congress.
Capricor Therapeutics presented promising long-term data on its experimental Duchenne muscular dystrophy treatment deramiocel at the 2026 World Muscle Society Congress, with findings suggesting meaningful preservation of upper limb function in affected patients.
The centerpiece of the presentation was a 24-month crossover analysis drawn from the HOPE-3 open-label extension study. Patients who had spent their first year on placebo before switching to deramiocel showed a 76% slowdown in upper limb decline compared with their own rate of deterioration during that placebo year, suggesting the drug's effect was measurable even against each patient's personal baseline.
Read more Fed Approves Isabella Bank Corporation Application →
Duchenne muscular dystrophy is a progressive, life-limiting genetic condition that systematically weakens muscle function over time. Upper limb capability is considered a critical quality-of-life marker for patients, particularly as the disease advances and mobility becomes increasingly restricted. Treatments that can slow functional loss in the arms represent a significant clinical priority.
The crossover design of the analysis is noteworthy because it uses each participant as their own control, a methodological approach that can reduce the confounding influence of patient-to-patient variability. Analysts have noted that such within-patient comparisons, while not a substitute for randomized controlled trial data, can offer a compelling signal of therapeutic benefit.
Capricor has been advancing deramiocel as a cell therapy candidate for Duchenne, and this latest dataset adds to the body of evidence the company is assembling in support of the treatment. Continue reading at GlobeNewswire - Industry News on Financial Services.
